Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC Patients | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC Patients	Neoplasm, Residual, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, neoplasm	Not yet recruiting	Phase 2	2026-07-16		NCT07709585

7 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Beijing Chest Hospital	17
First Affiliated Hospital of Xinjiang Medical University	42
Guang'anmen Hospital of China Academy of Chinese Medical Sciences	34
Guangdong Provincial Hospital of Traditional Chinese Medicine	39
Guangzhou University of Traditional Chinese Medicine	16
Sichuan Cancer Hospital and Research Institute	64
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine	4

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Guangdong Provincial Hospital of Chinese Medicine	Guangzhou	China	10